Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
AstraZeneca
Mallinckrodt
Baxter
Merck

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,200,604

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,200,604
Title: Sublingual buccal effervescent
Abstract:A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.
Inventor(s): Pather; Sathasivan Indiran (Plymouth, MN), Khankari; Rajendra K. (Maple Grove, MN), Eichman; Jonathan D. (Ann Arbor, MI), Robinson; Joseph R. (Madison, WI), Hontz; John (Plymouth, MN)
Assignee: Cima Labs Inc. (Minneapolis, MN)
Application Number:09/327,814
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,200,604
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;

Drugs Protected by US Patent 6,200,604

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-001 Sep 25, 2006 RX Yes No   Start Trial   Start Trial MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-002 Sep 25, 2006 RX Yes No   Start Trial   Start Trial MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-006 Mar 2, 2007 DISCN Yes No   Start Trial   Start Trial MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-003 Sep 25, 2006 RX Yes Yes   Start Trial   Start Trial MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Cephalon FENTORA fentanyl citrate TABLET;BUCCAL, SUBLINGUAL 021947-004 Sep 25, 2006 RX Yes No   Start Trial   Start Trial MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Merck
Baxter
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.